相关实验视频

Updated: May 5, 2026

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

由于局部晚期直肠癌,免疫标志物可以预测新辅助疗法和手术后的整体存活率和无病存活率

Miguel A Bonilla-Cozar¹, Anabel Garcia-Leon¹, Carlos J Garcia-Sanchez¹

¹Department of General Surgery, Hospital Universitario Virgen del Rocío, Sevilla, Spain.

Cirugia espanola

|August 30, 2025

概括

在局部发达的直肠癌患者中,中性粒对淋巴细胞 (NLR),血小板对淋巴细胞 (PLR) 和单细胞对淋巴细胞 (MLR) 的比率升高预示着更差的生存率. 结合这些免疫标志物可以更准确地预测新辅助治疗后的结果.

科学领域:

癌症学
免疫学
医学统计

背景情况:

在局部晚期直肠癌 (LARC) 患者的结局不同,尽管风险概况相似.
在LARC患者中,新辅助治疗反应和手术结果显著不同.
对LARC的预测生物标志物的研究对于个性化治疗策略至关重要.

研究的目的:

分析中性细胞对淋巴细胞 (NLR),血小板对淋巴细胞 (PLR) 和单细胞对淋巴细胞 (MLR) 的比率与LARC患者的存活率之间的关系.
确定这些免疫标志物的总生存率 (OS) 和无病生存率 (DFS) 的预测值.
评估这些比率的组合是否可以提高LARC患者预测结果的准确性.

主要方法:

在接受新辅助长期放射治疗和化疗的156名LARC患者的回顾性分析.
在新辅助治疗后和手术前获得的NLR,PLR和MLR比率的分析.
为每个指数分配截止点以评估与OS和DFS的关联.

主要成果:

中性细胞与淋巴细胞的比率 (NLR) 独立预测了5年的OS和DFS.
较高的NLR (> 6. 3) 与58. 9%的5年生存率 (P=. 019) 相关;较高的NLR (> 4. 72) 与57. 4%的5年生存率 (P=. 034) 相关.
患有NLR,PLR和MLR升高的患者表现明显差:五年后的生存率为25% (HR 3.16) 和五年后的死亡率为39. 4% (HR 2. 88).

结论:

在LARC患者中,手术前NLR,PLR和MLR比率的升高与新辅助治疗后的OS和DFS差异相关.
这三种免疫标志物的综合评估可以更准确地预测患者的存活率和复发率.
这些免疫标志物在定制LARC个性化治疗策略方面具有潜在的有用性.

关键词:

乳腺癌乳腺癌没有疾病的生存率单细胞与淋巴细胞的比例中性细胞与淋巴细胞的比率总体生存率血小板与淋巴细胞的比例结直肠癌全球生存没有疾病的生存单细胞 - 淋巴细胞指数指数中性细胞-淋巴细胞血小板-淋巴细胞指数

更多相关视频

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Published on: April 18, 2025

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...